BofA/Merrill Lynch Downgrades Seres Therapeutics (MCRB) to Underperform

August 3, 2018 6:10 AM

BofA/Merrill Lynch downgraded Seres Therapeutics (NASDAQ: MCRB) from Neutral to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found